APOE and BDNF as genetic risk markers for predicting the onset and development of cognitive deficits due to Alzheimer's disease

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00073449" target="_blank" >RIV/00159816:_____/20:00073449 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2020-3-3/apoe-and-bdnf-as-genetic-risk-markers-for-predicting-the-onset-and-development-of-cognitive-deficits-due-to-alzheimer-s-disease-122980/download?hl=cs" target="_blank" >https://www.csnn.eu/en/journals/czech-and-slovak-neurology-and-neurosurgery/2020-3-3/apoe-and-bdnf-as-genetic-risk-markers-for-predicting-the-onset-and-development-of-cognitive-deficits-due-to-alzheimer-s-disease-122980/download?hl=cs</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.14735/amcsnn2020257" target="_blank" >10.14735/amcsnn2020257</a>

Jazyk výsledku

čeština

Název v původním jazyce

APOE and BDNF as genetic risk markers for predicting the onset and development of cognitive deficits due to Alzheimer's disease

Popis výsledku v původním jazyce

Alzheimer&apos;s disease (AD) is a progressive neurodegenerative disorder that is typically initialized by neuronal death in the hippocampus and mediotemporal structures with characteristic episodic memory impairment. However, what is different among AD patients is the age of onset and progression of the disease. It has been suggested that the major modulators of these factors appear to be genetic polymorphisms in apolipoprotein E (APOE) and brain-derived neurotrophic factor (BDNF) genes. APOE 4 allele is the primary genetic determinant of risk for late-onset AD. BDNF Val66Met polymorphism has been shown to alter the risk for developing cognitive impairment and disease progression, both directly and indirectly through an interaction with the APOE genotype. The carriage of both risky variants APOE 4/BDNF Met was associated with episodic memory impairment and faster memory decline compared to the presence of only one or none of these high-risk polymorphisms. This information may be useful for improving the early-detection capability of individuals at risk of developing AD, as well as advancing our understanding of polymorphic combinations that predict the rate of disease progression. Some interventional studies also indicate potential for non-pharmacological interventions in disease prevention in high-risk individuals.

Název v anglickém jazyce

APOE and BDNF as genetic risk markers for predicting the onset and development of cognitive deficits due to Alzheimer's disease

Popis výsledku anglicky

Alzheimer&apos;s disease (AD) is a progressive neurodegenerative disorder that is typically initialized by neuronal death in the hippocampus and mediotemporal structures with characteristic episodic memory impairment. However, what is different among AD patients is the age of onset and progression of the disease. It has been suggested that the major modulators of these factors appear to be genetic polymorphisms in apolipoprotein E (APOE) and brain-derived neurotrophic factor (BDNF) genes. APOE 4 allele is the primary genetic determinant of risk for late-onset AD. BDNF Val66Met polymorphism has been shown to alter the risk for developing cognitive impairment and disease progression, both directly and indirectly through an interaction with the APOE genotype. The carriage of both risky variants APOE 4/BDNF Met was associated with episodic memory impairment and faster memory decline compared to the presence of only one or none of these high-risk polymorphisms. This information may be useful for improving the early-detection capability of individuals at risk of developing AD, as well as advancing our understanding of polymorphic combinations that predict the rate of disease progression. Some interventional studies also indicate potential for non-pharmacological interventions in disease prevention in high-risk individuals.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

<a href="/cs/project/LQ1605" target="_blank" >LQ1605: Translační medicína</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česká a slovenská neurologie a neurochirurgie

ISSN

1210-7859

e-ISSN

—

Svazek periodika

83

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

6

Strana od-do

257-262

Kód UT WoS článku

000571508700007

EID výsledku v databázi Scopus

—